Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats

Chen, Chun; Wang, Yang; Cai, Xiaodan; Zhang, Qi; Huang, Xiaoying; Xu, Hui; Yu, Fei; Chen, Chan; Lu, Yuanyuan; Zhang, Weixi; Yao, Dan; Yang, Lu; Ding, Cheng; Wang, Liangxing

doi:10.1016/j.lfs.2012.03.008

Cited by 29 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until that time, the benefits of resveratrol in the treatment of patients with CVDs will remain as is; holding great promise but not yet proven. Pre-treatment with resveratrol significantly reduced mean pulmonary artery pressure [73] A C C E P T E D M A N U S C R I P T…”

Section: Discussionmentioning

confidence: 99%

“…In addition, resveratrol has also been shown to reverse established pulmonary hypertension when it was administered 28 days after the monocrotaline injection [71,72]. In a model of pulmonary thromboembolisminduced pulmonary hypertension, two doses of resveratrol (10 mg/kg; IP) significantly reduced mean pulmonary artery pressure through down-regulation of monocyte chemo-attractant protein-1 (MCP-1), and P-p38 mitogen-activated protein kinase (MAPK) [73]. Together, these studies show that resveratrol has multiple beneficial effects on the vasculature and may hold promise for the treatment and/or prevention of systemic hypertension as well as pulmonary hypertension.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Zordoky

Robertson

Dyck

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

278

217

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. Despite advancements in diagnosis and treatment of cardiovascular disease, the incidence of cardiovascular disease is still rising. Therefore, new lines of medications are needed to treat the growing population of patients with cardiovascular disease. Although the majority of the existing pharmacotherapies for cardiovascular disease are synthesized molecules, natural compounds, such as resveratrol, are also being tested. Resveratrol is a non-flavonoid polyphenolic compound, which has several biological effects. Preclinical studies have provided convincing evidence that resveratrol has beneficial effects in animal models of hypertension, atherosclerosis, stroke, ischemic heart disease, arrhythmia, chemotherapy-induced cardiotoxicity, diabetic cardiomyopathy, and heart failure. Although not fully delineated, some of the beneficial cardiovascular effects of resveratrol are mediated through activation of silent information regulator 1 (SIRT1), AMP-activated protein kinase (AMPK), and endogenous anti-oxidant enzymes. In addition to these pathways, the anti-inflammatory, anti-platelet, insulin-sensitizing, and lipid-lowering properties of resveratrol contribute to its beneficial cardiovascular effects. Despite the promise of resveratrol as a treatment for numerous cardiovascular diseases, the clinical studies for resveratrol are still limited. In addition, several conflicting results from trials have been reported, which demonstrates the challenges that face the translation of the exciting preclinical findings to humans. Herein, we will review much of the preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular disease and provide information about the physiological and molecular signaling mechanisms involved. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Zordoky

Robertson

Dyck

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

278

217

View full text Add to dashboard Cite

show abstract

“…In line with this, the present study found that resveratrol treatment significantly suppressed the isoflurane-induced increase in the p-p38/p38 MAPK ratio in PC12 cells. Chun et al (29) suggested that resveratrol downregulates acute thromboembolism-induced pulmonary artery hypertension through p38 MAPK in rats.…”

Section: Discussionmentioning

confidence: 99%

Resveratrol protects neuronal cells from isoflurane‑induced inflammation and oxidative stress‑associated death by attenuating apoptosis via Akt/p38 MAPK signaling

Yang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The aim of the present study was to determine whether resveratrol protects neuronal cells from inflammation and isoflurane-induced oxidative stress-associated death via attenuating apoptosis via Akt/p38 mitogen-activated protein kinase (MAPK) signaling. The PC12 rat pheochromocytoma cell line was treated with 2% isoflurane + 21% O 2 + 5% CO 2 for 6 h and pre-treated with resveratrol (0-1,000 µM) for 0, 24 or 48 h prior to isoflurane treatment. An MTT assay, flow cytometry and ELISA of tumor necrosis factor-α, interleukin-6, malondialdehyde and superoxide dismutase revealed that resveratrol reduced growth inhibition, restrained apoptosis and suppressed inflammation and oxidative stress induced by isoflurane in PC12 cells. Pretreatment with resveratrol effectively reduced caspase-3 activity and inducible nitric oxide synthase protein expression in isoflurane-induced PC12 cells. In addition, western blot analysis demonstrated that resveratrol treatment significantly attenuated isoflurane-induced decreases in the activated phosphorylated (p)-Akt/Akt ratio and increases in the p-p38/p38 MAPK protein ratio in PC12 cells. These findings indicated that resveratrol was able to protect neuronal cells from isoflurane-induced inflammation and oxidative stress-associated death by attenuating apoptosis via Akt/p38 MAPK signaling.

show abstract

“…The present study illustrated that resveratrol administration is able to significantly suppress the expression of p-p38 in rats with STZ-DRMI. Chun et al (17) suggested that resveratrol was able to suppress acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 MAPK signaling in rats.…”

Section: Discussionmentioning

confidence: 99%

“…Traditionally, Chinese medicines such as Polygonum cuspidatum and fleece-flower roots, which are rich in resveratrol, have been used to treat and prevent hyperlipidemia and arteriosclerosis (16). A recent study demonstrated that resveratrol is an effective molecule which may be able to prevent cardiac dysfunction (17). The present study aimed to investigate whether the protective effect of resveratrol was able to improve cardiovascular functions in rats with diabetes.…”

Section: Introductionmentioning

confidence: 93%

Protective effects of resveratrol improve cardiovascular function in rats with diabetes

Yan

Sun

2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract.Resveratrol is a flavonoid with a stilbene structure that is able to suppress acute pulmonary thromboembolism-induced pulmonary artery hypertension. Furthermore, it possesses anti-cancer and antioxidant properties, is able to regulate blood lipids and increase life expectancy. In the present study, it was evaluated whether the protective effect of resveratrol was able to improve cardiovascular function in rats with diabetes. The effects of resveratrol on blood glucose, body weight, heart/body weight ratio, plasma triglyceride levels, heart rate, aspartate transaminase (AST)/alanine transaminase (ALT) ratio and total plasma insulin were evaluated. Levels of inflammation and oxidative stress were also evaluated using ELISA kits, and the expressions of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and phosphorylated (p)-p38 protein were evaluated via western blot analysis. The results demonstrated that administration of resveratrol in rats with diabetes-related myocardial infarction (DRMI) significantly reduced blood glucose, body weight, plasma triglyceride levels, heart rate and AST/ALT ratio (all P<0.01) and significantly increased total plasma insulin (P<0.01). Furthermore, resveratrol significantly reduced levels of inflammation factors (P<0.01) and malondialdehyde, a marker for oxidative stress, in rats with DRMI (P<0.01). Resveratrol significantly increased the expression of eNOS (P<0.01) and suppressed the expression of VEGF and p-p38 (both P<0.01) in rats with DRMI. These results suggest that treatment with resveratrol is able to improve cardiovascular function via inhibition of eNOS and VEGF, and suppression of p38 phosphorylation in rats with DRMI.

show abstract

Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats

Cited by 29 publications

References 25 publications

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Resveratrol protects neuronal cells from isoflurane‑induced inflammation and oxidative stress‑associated death by attenuating apoptosis via Akt/p38 MAPK signaling

Protective effects of resveratrol improve cardiovascular function in rats with diabetes

Contact Info

Product

Resources

About